Bulk Pharmaceutical API Sources for DYANAVEL XR

Bulk Pharmaceutical API Sources for DYANAVEL XR

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		HeV@@@RYyTYj`@@@@
NovoSeek		3007
AAA Chemistry		AR-1H6584
ABI Chem		AC1L1EYQ
ABI Chem		AC1Q5065

Bulk Active Pharmaceutical Ingredient (API) Sources for DYANAVEL XR

Last updated: July 27, 2025

---

Introduction

DYANAVEL XR, marketed by Takeda Pharmaceuticals, is an extended-release formulation of amphetamine sulfate indicated primarily for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged six and above, as well as in adolescents. As a long-acting stimulant, DYANAVEL XR's efficacy and safety hinge significantly on the quality of its active pharmaceutical ingredient (API). Reliable sourcing of amphetamine sulfate, the API of DYANAVEL XR, is critical for manufacturing, regulatory compliance, and supply chain stability. This article explores current and emerging bulk API sources for DYANAVEL XR, highlighting market dynamics, quality considerations, and industry practices.

---

Understanding the API: Amphetamine Sulfate

Amphetamine sulfate is a potent central nervous system stimulant classified under Schedule II of the Controlled Substances Act in the United States, underscoring its high potential for abuse and dependence.[1] Its manufacturing involves complex chemical synthesis, rigorous purification, and strict compliance with regulatory standards. Given its controlled status, sourcing involves licensed suppliers with robust security, traceability, and compliance frameworks.

---

Global Market Landscape for Amphetamine Sulfate API

The API for DYANAVEL XR is predominantly sourced from a handful of well-established manufacturers across North America, Europe, and Asia. The key factors influencing API sourcing include regulatory approvals, quality certifications, manufacturing capacity, legal compliance, and cost-efficiency.

North American Suppliers
The US-based pharmaceutical industry has a limited pool of manufacturers licensed to produce controlled substances at scale. Major players include:

• Cerilliant Corporation: Specializes in high-quality certified reference standards and APIs, including controlled substances, with compliance to US DEA regulations.[2]
• Alkaloida Chemical Group LLC: A recognized manufacturer with GMP-certified facilities capable of producing amphetamine sulfate under DEA registration.[3]

European Suppliers
European suppliers benefit from stringent manufacturing standards aligned with EMA regulations:

• BioAnalytical Ltd.: A UK-based manufacturer with approved production lines for controlled substances, supplying Amphetamine sulfate for pharmaceutical applications.[4]
• Janex Pharma: Finnish company known for API synthesis with licenses for controlled drug APIs, adhering to EMA Good Manufacturing Practices (GMP).[5]

Asian Suppliers
Asia, particularly China and India, forms a significant source of API globally due to cost advantages and expanding manufacturing capacity:

• Zhejiang Huahai Pharmaceutical Co., Ltd. (China): Has expanded API manufacturing capabilities, including controlled substances, with certifications aligning with international standards.[6]
• Sun Pharmaceutical Industries Ltd. (India): Operates API plants compliant with WHO GMP standards, producing amphetamine sulfate among their controlled substance APIs.[7]

---

Key Considerations in API Sourcing for DYANAVEL XR

Regulatory Compliance and DEA Registration

Given the classification of amphetamine sulfate, suppliers must possess DEA registration in the US or equivalent authorities in other jurisdictions, ensuring adherence to strict controlled substance regulations.

Quality Assurance and Certification

Suppliers must provide cGMP-certified APIs, along with comprehensive Certificates of Analysis (CoA), stability data, and absence of impurities. Quality considerations extend to endotoxin levels, residual solvents, and heavy metals.

Supply Chain Security and Traceability

The nature of controlled substances necessitates robust traceability, secure transportation logistics, and inventory controls. Traceability ensures compliance and mitigates diversion risks.

Pricing and Capacity

Cost considerations are significant, especially with potent APIs where manufacturing complexity drives expenses. Suppliers with scalable capacity and long-term supply commitments are preferred.

---

Challenges in API Sourcing for Controlled Substances

1. Regulatory Hurdles: Stringent regulatory oversight, including periodic inspections and reporting, deters new entrants.
2. Supply Disruptions: Political, logistical, or regulatory issues can cause shortages, impacting manufacturing continuity.
3. Authenticity and Counterfeit Risk: High-value controlled APIs are susceptible to counterfeit or adulteration, threatening safety and compliance.
4. International Trade Regulations: Export/import restrictions and customs hurdles can delay supply chains.

---

Emerging Trends

Vertical Integration and In-House Manufacturing

Some pharmaceutical companies are investing in in-house API production or exclusive agreements with suppliers to mitigate risks of supply disruptions.

API Biosynthesis Technologies

Research into novel biotechnological synthesis routes aims to improve yield, sustainability, and purity levels, although these are not yet mainstream for controlled substances like amphetamine sulfate.

Regulatory Harmonization and International Collaboration

International agencies are working towards harmonized standards, increasing efficiency in cross-border API procurement.

---

Conclusion

Securing a reliable bulk source of amphetamine sulfate for DYANAVEL XR remains a complex yet manageable task. Leading global suppliers, particularly those with strict regulatory compliance, robust quality systems, and secure supply chains, are preferred partners. As the pharmaceutical landscape evolves, manufacturers must stay vigilant to regulatory changes, geopolitical factors, and technological advances to ensure a steady, compliant supply of this potent API.

---

Key Takeaways

• The primary bulk source for DYANAVEL XR API (amphetamine sulfate) consists of a limited pool of licensed manufacturers with DEA registration and GMP certification.
• North American and European suppliers emphasize regulatory compliance, quality assurance, and traceability, whereas Asian suppliers offer cost advantages with expanding capacities.
• Navigating regulatory frameworks, maintaining high purity standards, and securing supply chain integrity are critical strategies for API procurement.
• Industry trends favor vertical integration, technological innovation, and international regulatory harmonization to mitigate supply risks.
• Continuous due diligence, supplier qualification, and regulatory vigilance are imperative for reliable API sourcing and uninterrupted DYANAVEL XR production.

---

FAQs

1. Why is amphetamine sulfate classified as a controlled substance, and how does it affect sourcing?
Amphetamine sulfate's high abuse potential classifies it as a Schedule II controlled substance, requiring special licensing, strict manufacturing oversight, and secure supply chain management, which limit available suppliers and increase compliance costs.

2. What quality certifications should a supplier of amphetamine sulfate possess?
Suppliers should hold GMP certification, DEA registration (for US suppliers), and provide Certificates of Analysis confirming compliance with pharmacopeia standards, purity, and absence of impurities.

3. Are Asian suppliers viable options for sourcing amphetamine sulfate?
Yes, provided they comply with international regulatory standards (e.g., WHO GMP) and hold appropriate licenses. Cost benefits and capacity enhancements make them attractive, but due diligence on regulatory compliance is essential.

4. How do geopolitical factors influence API sourcing for DYANAVEL XR?
Trade restrictions, export controls, and political instability can disrupt supply chains. Engaging multiple suppliers across regions mitigates risks and ensures continuity.

5. What are future considerations for API sourcing in the context of pharmaceutical manufacturing?
Advancements in biotechnological synthesis, increasing regulatory harmonization, and investments in in-house API production are likely to shape the sourcing landscape, emphasizing quality, security, and supply resilience.

---

References

1. U.S. Drug Enforcement Administration. (2023). Controlled Substances Act.
2. Cerilliant Corporation. (2023). Product Portfolio.
3. Alkaloida Chemical Group LLC. (2023). Certification and Licensing Details.
4. BioAnalytical Ltd. (2023). GMP Certification.
5. Janex Pharma. (2023). API Manufacturing Capabilities.
6. Zhejiang Huahai Pharmaceutical Co., Ltd. (2023). Regulatory Approvals.
7. Sun Pharmaceutical Industries Ltd. (2023). API Production Standards.